Roche ✓
Basel-headquartered pharma giant, dual-class voting shares, Swiss family-anchored.
At a Glance
- Legal name
- F. Hoffmann-La Roche AG
- Jurisdiction
- Switzerland (Canton of Basel-Stadt)
- Ownership
- public
- Listed on
- SIX (ROG)
- Employees
- 1000+
- Revenue (est.)
- $1B+
- Headquarters
- Grenzacherstrasse 124, 4070 Basel, Canton of Basel-Stadt, Switzerland
# Roche
Roche
F. Hoffmann-La Roche AG is one of the two Basel-anchored pharmaceutical giants that together define Switzerland's life-sciences cluster. Founded in 1896 by Fritz Hoffmann-La Roche, the company generated roughly CHF 60 billion in 2024 revenue across its Pharmaceuticals division (Genentech, Chugai, and in-house Basel operations) and its Diagnostics division (global leader in in-vitro diagnostics). Roche employs around 103,000 people globally and is a top-three pharma company by market capitalization.
The listed entity Roche Holding AG trades on SIX Swiss Exchange under ticker ROG and files sponsored ADRs traded OTC in the US under RHHBY. Roche's share structure is unusual: founding-family-linked heirs (the Hoffmann and Oeri families plus related interests) control the voting bearer shares, while public investors mostly hold non-voting participation certificates (Genussscheine). That dual-class structure has kept Roche immune to activist pressure and takeover attempts for decades and is one of the last major European examples of family-anchored pharma governance.
Operationally, Roche is Basel-based. The listed AG, the research labs, and group treasury all sit in Canton Basel-Stadt, the traditional Swiss pharmaceutical canton alongside Basel-Landschaft.
- 1
Share class engineering
Roche is the canonical example of how a Swiss Aktiengesellschaft can protect family control across generations while accessing global capital markets. Most listed companies in the US and UK are now prohibited from issuing dual-class shares at IPO or must sunset them within a decade. Swiss corporate law does not impose that constraint. Roche's founding families have maintained voting control since 1896 by keeping bearer shares (stimmrechtsaktien) in a family pool while issuing non-voting participation certificates to the public.
- 2
Share class engineering
This matters for Swiss structuring because it proves that cantonal law tolerates protective share classes even at megacap scale. Canton Basel-Stadt registers the Roche AG, which means the dual-class structure is explicitly sanctioned by a Swiss cantonal commercial registrar. Founders replicating this should note that the participation certificate (Genussschein) is a Swiss-specific instrument - it is not quite preferred stock in the US sense, it is not quite tracking stock, and it does not exist in UK, German, or French company law in the same form. US and UK investors often require education before accepting it.
- 3
Estonia e-Residency play
The second lesson is the Swiss-plus-ADR pattern. Roche lists its bearer shares on SIX and separately sponsors an OTC ADR program for US institutional access. This is the middle path between Nestle (Swiss-only, unsponsored ADRs) and Novartis (sponsored NYSE dual listing). The OTC route is cheaper to maintain, does not require SEC 20-F filings, and still gives US mutual funds clean access. For a mid-sized Swiss AG planning international capital raises, OTC-sponsored ADRs are usually the right first step before graduating to NYSE or NASDAQ.
- 4
Tax strategy
Third, Roche demonstrates the economic depth of Basel-Stadt as a canton. The cantonal corporate income tax rate runs around 13%, which combined with federal tax lands at roughly 13-14% all-in - competitive with Zug and below Zurich or Geneva. Basel-Stadt also provides dense life-sciences talent, proximity to European regulators, and specialised Zefix registrar experience with pharma-specific filings. Novartis chose the same canton for the same reasons.
Key People
Fritz Hoffmann-La Roche
Founder
From Wikidata
Thomas Schinecker
CEO
From Wikidata
Corporate Timeline
- Oct 1896Incorporation
Roche founded
Founded in 1896 by Fritz Hoffmann-La Roche.
Replicate Roche's structure in 4 steps
The formation playbook, distilled from how this company was actually set up.
German entity type
**Roche Holding AG** (Basel, Basel-Stadt) - the listed parent, Swiss Aktiengesellschaft, ticker ROG on SIX. Issues both voting bearer shares (family-controlled) and non-voting participation certificates (public float).
German entity type
**F. Hoffmann-La Roche AG** (Basel) - operating AG for the Swiss Pharmaceuticals division, owns most non-US IP.
Estonia e-Residency play
**Country and product subsidiaries** - Genentech Inc. (Delaware), Chugai Pharmaceutical (Tokyo-listed 61.5% owned), Roche Diagnostics Ltd, etc.
Comparable Companies
Recent News & Filings
- Despite data concerns, Roche’s oral SERD can still be largest product in company history: exec - Fierce PharmaFierce Pharma · 23 Apr 2026
- Europe risks falling further behind in medicine race, warns Roche CEO - ReutersReuters · 23 Apr 2026
- Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’ - BioSpaceBioSpace · 23 Apr 2026
- Roche First-Quarter Sales Drop, Hurt by Copycats and Currencies - Bloomberg.comBloomberg.com · 23 Apr 2026
- From debt to ‘acceptable’ prices: Roche CEO lists 3 reasons for sitting out Big Pharma M&A spree - Fierce BiotechFierce Biotech · 23 Apr 2026
Frequently Asked Questions
Is Roche still family-controlled?
Yes. The Hoffmann and Oeri family branches, together with their related family pool, hold a controlling block of voting bearer shares. Public investors mostly hold non-voting participation certificates (Genussscheine).
What is a Genussschein?
A participation certificate under Swiss corporate law. It gives economic rights (dividends, liquidation proceeds) but no voting rights. It is a Swiss-specific instrument and does not map cleanly to preferred stock or tracking stock in US or UK law.
How is Roche taxed compared with Novartis?
Both are headquartered in Canton Basel-Stadt and face essentially identical cantonal and federal corporate income tax rates, around 13-14% all-in. The meaningful tax differences sit in their respective international transfer-pricing structures.
Where does Roche trade in the US?
Roche trades via sponsored ADRs on the OTC market under ticker RHHBY. Unlike Novartis (NYSE: NVS), Roche does not maintain a primary US listing. The OTC route is cheaper and avoids SEC 20-F filing.
Sponsored Content Inquiries
Publish a long-form sponsored article about Roche or your related business on Corpy. Editorial-style, SEO-optimized, linked from our country and industry hubs.
Start a sponsored article